Skip to main content
Premium Trial:

Request an Annual Quote

Fisher s Organic Revenues Grow 3 Percent in Q1, Though Total Receipts Surge 35 Percent

NEW YORK, May 10 (GenomeWeb News) - Fisher Scientific yesterday reported 3-percent year-over-year organic revenue growth in the first quarter, amid overall revenue growth of 35 percent.


Fisher's total revenues for the first quarter increased to $1.35 billion from $1 billion in the same period in 2004. Excluding foreign currency exchange benefits, the company's Q1 sales were $1.34 billion.


Revenues from scientific products and services excluding foreign currency benefits increased 31 percent to $970.7 million. However, the company said that approximately 2 percent of this revenue growth was organic.


For healthcare products and services, Fisher reported sales of $335.8 million after foreign currency benefits, up 48 percent from the prior year's quarter. However, approximately 5 percent of this increase was organic, according to Fisher.


Fisher's revenues for its laboratory-workstations segment increased 21 percent to $46.3 million. Fisher did not break out organic growth for this segment.


The company's Q1 net income increased to $77 million, or $.64 per basic share, from $34.6 million, or $.54 per basic share in the first quarter last year.


As of March 31, Fisher had $237 million in cash and cash equivalents on hand.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.